Core Insights - Jiaxian Co., Ltd. (920489) reported a net financing purchase of 1.1558 million yuan on August 21, 2025, with a financing balance of 48.519 million yuan, marking a continuous net purchase over the last three trading days totaling 10.2491 million yuan [1][2][3] Financing Activity - On August 21, 2025, the net financing purchase was 1.1558 million yuan, with a financing balance of 48.519 million yuan, representing 2.39% of the circulating market value [2] - The financing balance increased by 2.44% compared to the previous day [3][4] - Over the last 20 trading days, there were 13 days with net financing purchases, indicating a positive trend in investor sentiment [1] Historical Financing Data - The financing balance and net purchases over the last few trading days are as follows: - August 20: Net purchase of 712,900 yuan, balance of 47.3632 million yuan [2] - August 19: Net purchase of 8.3804 million yuan, balance of 46.6503 million yuan [2] - August 18: Net purchase of 1.5900 million yuan, balance of 38.2699 million yuan [2] - August 15: Net repayment of 1.5336 million yuan, balance of 36.6799 million yuan [2][4] Margin Trading Knowledge - Current requirements for individual investors to participate in margin trading include having at least six months of trading experience and an average asset of 500,000 yuan over the last 20 trading days [5]

Group 1 - The A-share photoresist sector is active in early trading, with Kangpeng Technology rising over 7% [1] - Jiuri New Materials and Yida Co., Ltd. both increased by more than 4% [1] - Other companies such as Shanghai Xinyang, Jingrui Electric Materials, Jiaxian Co., Ltd., and Guangxin Materials also experienced gains [1]

Group 1: Company Performance - In Q1 2025, the company's sales revenue and sales volume increased month-on-month, but year-on-year performance declined due to a high profit base from the previous year and reduced downstream production [4] - The company operates in a cyclical industry, currently at the bottom of the cycle, with market prices stabilizing at low levels, indicating limited further decline potential [4] Group 2: Equity and Consolidation - The company acquired a 7.5% stake in Yingtemei, resulting in a total ownership of 37.5% and becoming its controlling shareholder; however, Yingtemei will not be included in the consolidated financial statements for Q1 2025 [5] Group 3: Project Development - Yingtemei has approximately 7 projects in reserve, with the second phase focusing on domestic substitution in the electronic materials sector, and preliminary evaluations for project construction are underway [6] Group 4: Production Capacity and Product Information - The main products are DBM and SBM, with a combined capacity of about 10,000 tons; SBM is a high-end product used in food, pharmaceuticals, and toys, while DBM is used in industrial applications [7] - The company is facing challenges due to insufficient downstream demand and intensified market competition, leading to declining product prices [7] Group 5: Future Development Plans - The company aims to maintain and strengthen its traditional PVC environmental stabilizers and additives business while enhancing core competitiveness and market share [8] - Plans include building new material production lines focused on domestic substitution and accelerating the second phase of Yingtemei's project to create a new materials industry cluster [8][9] - The company will continue to deepen cooperation with strategic partners to enhance its diversified layout and overall strength [9]

Financial Performance - The company reported a basic earnings per share of 0.0400 yuan for Q1 2025, a decrease of 50% compared to 0.0800 yuan in Q1 2024 [1] - Net profit for Q1 2025 was 0.06 billion yuan, down 45.45% from 0.11 billion yuan in Q1 2024 [1] - Operating revenue for Q1 2025 was 1.29 billion yuan, a decline of 12.24% from 1.47 billion yuan in Q1 2024 [1] - The return on equity (ROE) decreased to 1.12% in Q1 2025 from 2.10% in Q1 2024, representing a decline of 46.67% [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 787.42 million shares, accounting for 9.18% of the circulating shares, with a decrease of 52.34 million shares compared to the previous period [1] - The largest shareholder, Bengbu Yuanda Innovation and Entrepreneurship Investment Co., Ltd., holds 345.45 million shares, representing 4.03% of total share capital, with a reduction of 40.16 million shares [2] - New entrants to the top ten shareholders include Wang Quanjun with 68.59 million shares (0.80%) and Li Fei with 55.71 million shares (0.65%) [2] Dividend Policy - The company has decided not to distribute dividends or transfer shares in the current period [3]

证券代码：430489 证券简称：佳先股份 公告编号：2025-041 安徽佳先功能助剂股份有限公司 第五届监事会第十六次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 本次会议的召集、召开符合《公司法》及《公司章程》中有关规定。 4.发出监事会会议通知的时间和方式：2025 年 4 月 18 日以书面结合通讯方式发 出 5.会议主持人：监事会主席杨爱玲 6.召开情况合法合规的说明： （一）会议召开情况 1.会议召开时间：2025 年 4 月 29 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 （一）审议通过《关于公司 2025 年第一季度报告的议案》 1.议案内容： 具体内容详见公司于 4 月 29 日在北京证券交易所官方信息披露平台 （https://www.bse.cn）披露的《2025 年第一季度报告》（公告编号：2025-042）。 2.议案表决结果：同意 3 票；反对 ...

一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 29 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 证券代码：430489 证券简称：佳先股份 公告编号：2025-040 安徽佳先功能助剂股份有限公司 第五届董事会第二十一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 具体内容详见公司于 4 月 29 日在北京证券交易所官方信息披露平台 （https://www.bse.cn）披露的《2025 年第一季度报告》（公告编号：2025-042）。 4.发出董事会会议通知的时间和方式：2025 年 4 月 18 日以书面结合通讯方 式发出 5.会议主持人：董事长李兑 6.会议列席人员：公司监事、高级管理人员和董事会秘书 7.召开情况合法合规的说明： 本次会议的召集、召开程序符合《公司法》和《公司章程》的有关规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 二、议案审议情况 （一）审议通过《关于公司 2025 年第一 ...

Financial Performance - The company's basic earnings per share decreased by 40% from 0.15 yuan in 2023 to 0.09 yuan in 2024 [1] - Net profit fell by 40% to 0.12 billion yuan in 2024 from 0.20 billion yuan in 2023 [1] - The return on equity dropped significantly by 41.31%, from 3.97% in 2023 to 2.33% in 2024 [1] - Total revenue increased by 7.28% to 5.75 billion yuan in 2024 compared to 5.36 billion yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 839.76 million shares, accounting for 9.8% of the circulating shares, with a decrease of 658.27 million shares from the previous period [1] - Notable changes in the top shareholders include a decrease of 1.06 million shares for the largest shareholder, and new entries from three individuals [2] Dividend Distribution - The company announced a dividend distribution plan of 1.8 yuan per share (including tax) [3]

安徽佳先功能助剂股份有限公司 证券代码：430489 证券简称：佳先股份 公告编号：2025-029 关于预计 2025 年日常性关联交易的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 日常性关联交易预计情况 （一） 预计情况 单位：元 | 关联交易类别 | 主要交易 | | | 预计 2025 年发生金额 | （2024）年与关联 | 预计金额与上年实际发 | | --- | --- | --- | --- | --- | --- | --- | | 购买原材料、 | 内容 购 | 买 | 蒸 | | 方实际发生金额 | 生金额差异较大的原因 | | 燃料和动力、 接受劳务 | 汽、电力、 原材料 | | | 160,150,000.00 | 68,435,020.41 | | | 销售产品、商 | 销售产品 | | | | | | | 品、提供劳务 | | | | 100,000,000.00 | 1,555,004.42 | 主要系将英特美纳入合 | | 委托关联方销 | | | | ...

安徽佳先功能助剂股份有限公司 关于 2025 年度向银行申请综合授信额度的公告 证券代码：430489 证券简称：佳先股份 公告编号：2025-027 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、银行综合授信额度的情况 为满足公司及子公司日常经营和业务发展需要，公司及合并报表范围内子公 司 2025 年度拟向各银行申请合计不超过 5.5 亿元的综合授信及用信额度（授信 额度包括新增授信及原有授信的展期或者续约，在不超过总授信额度范围内，最 终以公司与银行实际发生的融资金额为准）。授信期限自公司 2024 年度股东大 会审议批准之日起至 2025 年度股东大会召开之日有效，授信额度可循环使用， 且可以在不同银行间进行调整。 综合授信额度用于办理日常生产经营所需的流动资金贷款、项目贷款、并购 贷款、票据贴现、开具银行承兑汇票、银行保函、银行保理、信用证等业务。具 体合作金融机构及最终融资金额以及融资形式后续将与有关金融机构进一步协 商确定，以正式签署的协议或合同为准。 二、对公司的影响 公司及合并 ...

证券代码：430489 证券简称：佳先股份 公告编号：2025-008 安徽佳先功能助剂股份有限公司 第五届董事会第二十次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 23 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出董事会会议通知的时间和方式：2025 年 4 月 11 日以书面结合通讯方 式发出 5.会议主持人：董事长李兑 6.会议列席人员：公司监事、高级管理人员和董事会秘书 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开程序符合《公司法》和《公司章程》的有关规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 二、议案审议情况 本议案不涉及关联交易事项，无需回避表决。 4.提交股东大会表决情况： 本议案尚需提交股东大会审议。 （二）审议通过《关于公司 2024 年度总经理工作报告的议案》 1.议案内容： （一）审议通过《关于公司 202 ...